The Limited Times

Now you can see non-English news...

Corona: Curevac starts approval process for vaccines - production is already in full swing

2021-02-25T08:16:46.623Z


The fight against vaccine shortages is slowly improving. Now the Tübingen company Curevac is also entering the approval process.


The fight against vaccine shortages is slowly improving.

Now the Tübingen company Curevac is also entering the approval process.

Tübingen - The Tübingen biotech company Curevac has started the approval process for its Corona * vaccine candidate.

The company announced on Friday morning that the responsible European Medicines Agency (EMA) was provided with the first results as part of a rolling process.

The rolling process is intended to significantly accelerate the testing and approval of urgently needed vaccines.

The companies continuously hand over data to the supervisory authorities during their ongoing studies instead of collecting them and only handing them over at the end.

According to Curevac, data from the first pre-clinical tests are now available to the EMA.

The key results from the ongoing Phase III study should be available to the EMA by the beginning of April, a spokesman told Merkur.de * on Friday.

According to earlier information, Curevac is hoping for approval of its vaccine candidate in the second quarter.

So far, the Covid-19 vaccines from Biontech and its partner Pfizer, Moderna and AstraZenaca have been approved within the EU.

A rolling approval process for another possible vaccine from the US manufacturer Novavax is currently in progress.

In addition, observers expect that Johnson & Johnson and its daughter Janssen will soon submit an application for approval to the EMA.

The authority has received the first data packages from Janssen.

The US pharmaceutical giant applied for emergency approval in the USA at the beginning of February.

Another corona vaccine could now follow in the EU with Curevac.

Curevac: Vaccine production is already in full swing

At the Tübingen company, production of the new vaccine candidate is already running at full speed.

In order to further increase capacities, Curevac wants to work with other companies, including Bayer, Wacker Chemie and Fareva.

The company is also building a completely new production facility at its headquarters.

It is scheduled to start operating in 2022.

Similar to the Mainz competitor 

Biontech

 ,

Curevac

has also specialized in the development of messenger nucleic acids (

mRNA

).

In this novel approach, messengers are supposed to bring genetic blueprints for the production of unimaginably tiny amounts of antigens into the cells.

The proteins produced should trigger a defense reaction of the immune system, which should then also

 protect

the body against viruses such as the coronavirus 

SARS-CoV-2

.

According to Curevac, the first interim results indicate a "very high effectiveness".

In addition, the requirements for cooling are apparently considerably lower than those of Biontech, for example.

*

Merkur.de

is part of the Ippen Digital network.

Source: merkur

All news articles on 2021-02-25

You may like

News/Politics 2024-03-16T18:46:42.470Z
News/Politics 2024-03-18T14:18:09.201Z

Trends 24h

News/Politics 2024-03-27T16:45:54.081Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.